Journal of Tuberculosis and Lung Disease ›› 2022, Vol. 3 ›› Issue (4): 315-319.doi: 10.19983/j.issn.2096-8493.20220092
• Review Articles • Previous Articles Next Articles
Received:
2022-05-25
Online:
2022-08-20
Published:
2022-08-16
Contact:
Zhai Xiaowen
E-mail:zhaixiaowendy@163.com
CLC Number:
Qian Xiaowen, Zhai Xiaowen. Hematopoietic stem cell transplantation and tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(4): 315-319. doi: 10.19983/j.issn.2096-8493.20220092
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.jtbld.cn/EN/10.19983/j.issn.2096-8493.20220092
[1] | 黄晓军. 实用造血干细胞移植. 2版. 北京: 人民卫生出版社, 2019: 3-10. |
[2] |
Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol, 2020, 40(1): 66-81. doi: 10.1007/s10875-020-00758-x.
doi: 10.1007/s10875-020-00758-x pmid: 32048120 |
[3] |
World Health Organization. BCG vaccine: WHO position paper, February 2018-Recommendations. Vaccine, 2018, 36(24): 3408-3410. doi: 10.1016/j.vaccine.2018.03.009.
doi: S0264-410X(18)30345-1 pmid: 29609965 |
[4] |
王淼, 孙炜玮, 李克莉, 等. 2015—2019年中国卡介苗疑似预防接种异常反应监测. 中国疫苗和免疫, 2021, 27(5): 594-598. doi: 10.19914/j.CJVI.2021106.
doi: 10.19914/j.CJVI.2021106 |
[5] |
Fekrvand S, Yazdani R, Olbrich P, et al. Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-Vaccine-Derived Complications: A Systematic Review. J Allergy Clin Immunol Pract, 2020, 8(4): 1371-1386. doi: 10.1016/j.jaip.2020.01.038.
doi: S2213-2198(20)30096-9 pmid: 32006723 |
[6] |
Castagnoli R, Delmonte OM, Calzoni E, et al. Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives. Front Pediatr, 2019, 7: 295. doi: 10.3389/fped.2019.00295.
doi: 10.3389/fped.2019.00295 pmid: 31440487 |
[7] |
Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet, 1968, 2(7583):1366-1369. doi: 10.1016/s0140-6736(68)92673-1.
doi: 10.1016/s0140-6736(68)92673-1 pmid: 4177932 |
[8] |
Rivers L, Gaspar HB. Severe combined immunodeficiency: recent developments and guidance on clinical management. Arch Dis Child, 2015, 100(7): 667-672. doi: 10.1136/archdischild-2014-306425.
doi: 10.1136/archdischild-2014-306425 pmid: 25564533 |
[9] |
Gaspar HB, Qasim W, Davies EG, et al. How I treat severe combined immunodeficiency. Blood, 2013, 122(23): 3749-3758. doi: 10.1182/blood-2013-02-380105.
doi: 10.1182/blood-2013-02-380105 pmid: 24113871 |
[10] |
Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol, 2014, 133(4): 1134-1141. doi: 10.1016/j.jaci.2014.02.028.
doi: 10.1016/j.jaci.2014.02.028 pmid: 24679470 |
[11] |
Pai SY, Logan BR, Griffith LM, et al.Transplantation outcomes for severe combined immunodeficiency, 2000—2009 N Engl J Med, 2014, 371(5): 434-446. doi: 10.1056/NEJMoa1401177.
doi: 10.1056/NEJMoa1401177 URL |
[12] |
Currier R, Puck JM. SCID newborn screening: What we’ve learned. J Allergy Clin Immunol, 2021, 147(2):417-426. doi: 10.1016/j.jaci.2020.10.020.
doi: 10.1016/j.jaci.2020.10.020 pmid: 33551023 |
[13] |
Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol, 2010, 126(3): 602-610. doi: 10.1016/j.jaci.2010.06.015.
doi: 10.1016/j.jaci.2010.06.015 pmid: 20673987 |
[14] |
Haddad E, Logan BR, Griffith LM, et al. SCID genotype and 6-month posttransplant CD 4 count predict survival and immune recovery. Blood, 2018, 132(17):1737-1749. doi: 10.1182/blood-2018-03-840702.
doi: 10.1182/blood-2018-03-840702 pmid: 30154114 |
[15] |
Antoine C, Müller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99 . Lancet, 2003, 316(9357):553-560. doi: 10.1016/s0140-6736(03)12513-5.
doi: 10.1016/s0140-6736(03)12513-5 |
[16] |
Fernandes JF, Rocha V, Labopin M, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood. Blood, 2012, 119(12):2949-2955. doi: 10.1182/blood-2011-06-363572.
doi: 10.1182/blood-2011-06-363572 pmid: 22308292 |
[17] |
Chiesa R, Gilmour K, Qasim W, et al. Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol, 2012, 156(5):656-666. doi: 10.1111/j.1365-2141.2011.08994.x.
doi: 10.1111/j.1365-2141.2011.08994.x URL |
[18] |
Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol, 2007, 19(5):318-330. doi: 10.1016/j.smim.2007.10.004.
doi: 10.1016/j.smim.2007.10.004 pmid: 18023361 |
[19] |
Yu HH, Yang YH, Chiang BL. Chronic Granulomatous Disease: a Comprehensive Review. Clin Rev Allergy Immunol, 2021, 61(2):101-113. doi: 10.1007/s12016-020-08800-x.
doi: 10.1007/s12016-020-08800-x URL |
[20] |
Conti F, Lugo-Reyes SO, Blancas Galicia L, et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol, 2016, 138(1):241-248. doi: 10.1016/j.jaci.2015.11.041.
doi: 10.1016/j.jaci.2015.11.041 URL |
[21] |
Dunogué B, Pilmis B, Mahlaoui N, et al. Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. Clin Infect Dis, 2017, 64(6):767-775. doi: 10.1093/cid/ciw837.
doi: 10.1093/cid/ciw837 URL |
[22] |
Cole T, Pearce MS, Cant AJ, et al. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol, 2013, 132(5): 1150-1155. doi: 10.1016/j.jaci.2013.05.031.
doi: 10.1016/j.jaci.2013.05.031 URL |
[23] |
Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, 2014, 383(9915):436-448. doi: 10.1016/S0140-6736(13)62069-3.
doi: 10.1016/S0140-6736(13)62069-3 URL |
[24] |
Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood, 2016, 128(3):440-448. doi: 10.1182/blood-2016-03-704015.
doi: 10.1182/blood-2016-03-704015 pmid: 27216217 |
[25] |
Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. New Engl J Med, 1996, 335(26): 1956-1961. doi: 10.1056/NEJM199612263352604.
doi: 10.1056/NEJM199612263352604 pmid: 8960475 |
[26] |
Das J, Banday AZ, Shandilya J, et al. An updated review on Mendelian susceptibility to mycobacterial diseases-a silver jubilee celebration of its first genetic diagnosis. Expert Rev Clin Immunol, 2021, 17(10): 1103-1120. doi: 10.1080/1744666X.2021.1956314.
doi: 10.1080/1744666X.2021.1956314 URL |
[27] |
Bustamante J, Boisson-Dupuis S, Abel L, et al. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol, 2014, 26(6):454-470. doi: 10.1016/j.smim.2014.09.008.
doi: 10.1016/j.smim.2014.09.008 pmid: 25453225 |
[28] |
Bax HI, Freeman AF, Ding L, et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol, 2013, 33(5):991-1001. doi: 10.1007/s10875-013-9882-5.
doi: 10.1007/s10875-013-9882-5 pmid: 23512243 |
[29] |
Olbrich P, Martínez-Saavedra MT, Perez-Hurtado JM, et al.Diagnostic and therapeutic challenges in a child with complete Interferon-γ Receptor 1 deficiency Pediatr Blood Cancer, 2015, 62(11):2036-2039. doi: 10.1002/pbc.25625.
doi: 10.1002/pbc.25625 pmid: 26173802 |
[30] |
Moilanen P, Korppi M, Hovi L, et al. Successful hematopoietic stem cell transplantation from an unrelated donor in a child with interferon gamma receptor deficiency. Pediatr Infect Dis J, 2009, 28(7):658-660. doi: 10.1097/INF.0b013e318195092e.
doi: 10.1097/INF.0b013e318195092e pmid: 19451859 |
[31] |
Zerbe CS, Dimitrova D, Gea-Banacloche JJ, et al. Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency. J Clin Immunol, 2020, 40(7):1045-1047. doi: 10.1007/s10875-020-00826-2.
doi: 10.1007/s10875-020-00826-2 URL |
[32] |
Mamishi S, Pourakbari B, Moradzadeh M, et al. Prevalence of active tuberculosis infection in transplant recipients: A systematic review and meta-analysis. Microb Pathog, 2020, 139:103894. doi: 10.1016/j.micpath.2019.103894.
doi: 10.1016/j.micpath.2019.103894 URL |
[33] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva:World Health Organization, 2018. |
[34] |
de Oliveira Rodrigues M, de Almeida Testa LH, Dos Santos ACF, et al. Latent and active tuberculosis infection in allogeneic hematopoietic stem cell transplant recipients: a prospective cohort study. Bone Marrow Transplant, 2021, 56(9): 2241-2247. doi: 10.1038/s41409-021-01329-3.
doi: 10.1038/s41409-021-01329-3 URL |
[35] |
Kimberlin D, Brady M, Jackson M. Red Book: 2018—2021 Report of the Committee on Infectious Diseases. 31st Ed. Itasca:American Academy of Pediatrics, 2018:829-853. doi: 10.1542/9781610021470.
doi: 10.1542/9781610021470 |
[36] |
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant, 2009, 15(10):1143-1238. doi: 10.1016/j.bbmt.2009.06.019.
doi: 10.1016/j.bbmt.2009.06.019 URL |
[37] |
Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med, 2014, 190(10):1168-1176. doi: 10.1164/rccm.201405-0967OC.
doi: 10.1164/rccm.201405-0967OC URL |
[38] |
Lee YM, Lee SO, Choi SH, et al. A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect, 2014, 69(2):165-173. doi: 10.1016/j.jinf.2014.02.019.
doi: 10.1016/j.jinf.2014.02.019 URL |
[39] |
中华医学会结核病学分会, 中国防痨协会学校与儿童结核病防治专业分会. 卡介苗不良反应临床处理指南. 中国防痨杂志, 2021, 43(6): 532-538. doi: 10.3969/j.issn.1000-6621.2021.06.002.
doi: 10.3969/j.issn.1000-6621.2021.06.002 |
[40] |
Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J, 2012, 40(4):990-1013. doi: 10.1183/09031936.00000712.
doi: 10.1183/09031936.00000712 pmid: 22496318 |
[41] |
Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol, 2014, 133(4): 1134-1141. doi: 10.1016/j.jaci.2014.02.028.
doi: 10.1016/j.jaci.2014.02.028 pmid: 24679470 |
[1] | Chen Yu, Li Xiaorui, Wang Miaoran, Zhang Yuqi, Liu Chang, Wang Zhaohua, Shi Jie, Fan Lichao, Yin Zhihua, Xie Jianping. The research progress on the role of metal ions in tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 102-112. |
[2] | Xu Yannan, Fang Zihao, Zhao Wenli, Zheng Jiaxiong, Liu Suyang, Lin Jianxiong, Ji Liwei, Chang Qiaocheng. Characterisation of isoniazid-resistant Mycobacterium tuberculosis mutations in China [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 14-21. |
[3] | Wan Ying, Pang Xuewen, Zhang Fan. Evaluation on effect of health promotion for tuberculosis prevention and control in Tianjin City from 2010 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 22-29. |
[4] | Zhao Yongnian, Zhang Lijie, Wang Tongmin. Analysis of the epidemiological characteristics of reported pulmonary tuberculosis in Xinjiang Production and Construction Corps, 2014—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 30-34. |
[5] | Zheng Jianli, Wu Yumei, Zhang Shili, Du Zixian, Li Turong, Chen Shisheng, Lin Wenge. Cost-effectiveness analysis of active tuberculosis screening among high-risk populations in Longyan City, Fujian Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 35-39. |
[6] | Yang Yan, Dong Wen, Chen Jianjun, Zhang Yu. Epidemiologic characteristics of pulmonary tuberculosis in Zhuxi County, Shiyan City (2014-2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 40-45. |
[7] | Qi Wei, Zhao Enyi. The epidemic characteristics and the trends of pulmonary tuberculosis in elderly and non-elderly in central urban area, Tianjin from 2006 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 46-54. |
[8] | Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60. |
[9] | Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67. |
[10] | Gu Jinhua, Zhang Panpan. Evaluation of the application value of three detection methods for Mycobacterium tuberculosis in a comprehensive hospital [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 68-72. |
[11] | Yan Wenhua, Chen Wenjun. The value of digital health education in the preventive management of caregivers of patients with bacterial positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 73-78. |
[12] | Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13. |
[13] | Zhang Ying, Guo Chunhui. Research progress in the treatment of tuberculous tracheobronchial stenosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 87-93. |
[14] | Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101. |
[15] | Hu Xinyang, Gao Jingtao. Interpretation of WHO global tuberculosis report 2024 [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 500-504. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||